Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord DrugsBOM:538965 +1.38%67 Days Payable is 18.91 as of Mar. 2026, which is 69% below its 10-year median of 61.56. GuruFocus rates BOM:538965 with a GF Score™ of 67/100 and a GF Value™ of ₹60.93 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 927 Drug Manufacturers companies, Concord Drugs ranks worse than 78.96% on this metric.
The historical data trend for Concord Drugs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Drugs Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Days Payable distribution charts can be found below:
* The bar in red indicates where Concord Drugs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Concord Drugs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Drugs (BOM:538965) has a Days Payable of 18.91 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Concord Drugs and its competitors. This is 69% below median its historical median of 61.56. Over the past decade, Concord Drugs' Days Payable has ranged from 39.64 to 502.19. According to the industry distribution chart, Concord Drugs ranks #732 out of 927 companies in the Drug Manufacturers industry, placing it in the top 79%.
Is Concord Drugs' Days Payable too high?
Concord Drugs' current Days Payable of 18.91 is 69% below median its 10-year median of 61.56. Over the past 10 years, this metric has ranged from a low of 39.64 to a high of 502.19. The Drug Manufacturers industry median Days Payable is 90.16. Concord Drugs' value of 18.91 is 79% below this industry median. Based on the distribution chart, Concord Drugs ranks #732 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Concord Drugs has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Concord Drugs ranks #732 out of 927 companies for Days Payable. This places Concord Drugs in the lower half of its industry. The industry median Days Payable is 90.16. Concord Drugs' value of 18.91 is 79% below this benchmark. Historically, Concord Drugs' own Days Payable has ranged from 39.64 to 502.19 over the past decade. While the company's 10-year median is 61.56 vs. the industry median of 90.16, Concord Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.16, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Drugs's current Days Payable of 18.91 is 79% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Concord Drugs and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Drugs's current Days Payable is 18.91, which is 69% below median its own 10-year median of 61.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.93, compared to a current price of ₹71.23 — trading 16.9% above its estimated fair value. The current Days Payable is 18.91, which is 69% below median its 10-year median of 61.56 and 79% below the Drug Manufacturers industry median of 90.16. Concord Drugs' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Days Payable is 18.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Drugs (BOM:538965) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued.
The current stock price of ₹71.23 is trading 16.9% above its estimated GF Value™ of ₹60.93.
GuruFocus considers Concord Drugs to be Modestly Overvalued.
Key valuation signals for BOM:538965:
Days Payable: 18.91 (69% below median its 10-year median of 61.56)
GF Value™: ₹60.93 vs. price of ₹71.23 (16.9% above fair value)
Industry Position: 79% below the Drug Manufacturers median (#732 of 927)
No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score
Get the complete analysis for BOM:538965
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538965 has been successfully added to your 
